Source:http://linkedlifedata.com/resource/pubmed/id/15375659
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-11-1
|
pubmed:abstractText |
Little is known about CD117 prevalence and clinicopathological implications in pulmonary large-cell neuroendocrine carcinoma. We studied CD117 immunoreactivity in surgical specimens from 39 large-cell neuroendocrine carcinomas of stages I-III and 27 limited-disease small-cell carcinomas, 56 typical and atypical carcinoids of the lung, and 10 neuroendocrine tumorlets, including the membrane and cytoplasmic immunostaining patterns. Membrane CD117 immunoreactivity in 5% or more tumor cells was documented in 30 (77%) large-cell neuroendocrine carcinomas and 18 (67%) small-cell carcinomas and 4 (7%) carcinoids, whereas cytoplasmic labeling was seen in 17 (44%) large-cell neuroendocrine carcinomas, 19 (70%) small-cell carcinomas, and 3 (5%) carcinoids. None of the neuroendocrine cells of the normal bronchial epithelium and of 10 tumorlets showed any CD117 immunoreactivity. Cytoplasmic immunostaining was more prevalent in small-cell carcinomas, whereas membrane labeling did not differ between the two types of high-grade carcinomas. Downregulation of CD117 by neoadjuvant chemotherapy was seen in large-cell neuroendocrine carcinomas but not small-cell carcinomas. Multiple linear regression analysis demonstrated a marginal association between cytoplasmic CD117 immunoreactivity and regional lymph node metastasis in small-cell carcinomas but not large-cell neuroendocrine carcinomas. There was no association between CD117 immunoreactivity and survival in either small-cell carcinoma or large-cell neuroendocrine carcinoma patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0945-6317
|
pubmed:author |
pubmed-author:BresaolaEnricaE,
pubmed-author:IannucciAntonioA,
pubmed-author:LeonMaria ElenaME,
pubmed-author:MasulloMicheleM,
pubmed-author:PasiniFeliceF,
pubmed-author:PelosiGiuseppeG,
pubmed-author:SonzogniAngelicaA,
pubmed-author:SpaggiariLorenzoL,
pubmed-author:VeronesiGiuliaG,
pubmed-author:VialeGiuseppeG
|
pubmed:issnType |
Print
|
pubmed:volume |
445
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
449-55
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:15375659-Aged,
pubmed-meshheading:15375659-Carcinoma, Small Cell,
pubmed-meshheading:15375659-Female,
pubmed-meshheading:15375659-Humans,
pubmed-meshheading:15375659-Immunohistochemistry,
pubmed-meshheading:15375659-Lung Neoplasms,
pubmed-meshheading:15375659-Lymphatic Metastasis,
pubmed-meshheading:15375659-Male,
pubmed-meshheading:15375659-Middle Aged,
pubmed-meshheading:15375659-Neuroendocrine Tumors,
pubmed-meshheading:15375659-Proto-Oncogene Proteins c-kit
|
pubmed:year |
2004
|
pubmed:articleTitle |
CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas.
|
pubmed:affiliation |
Division of Pathology and Laboratory Medicine, European Institute of Oncology, Via G. Ripamonti 435, 20141 Milan, Italy. giuseppe.pelosi@ieo.it
|
pubmed:publicationType |
Journal Article,
Comparative Study
|